To encourage responsible and
appropriate use of Carotid Artery Stenting (CAS) with embolic
protection, CMS issued a Decision Memo for Carotid Artery Stenting
on March 17, 2005. As a result, Medicare covers PTA of the carotid
artery concurrent with the placement of an FDA-approved carotid
stent with embolic protection for the following: •Patients who are
at high risk for CEA and who also have symptomatic carotid artery
stenosis >70 %. Coverage is limited to procedures performed
using FDA-approved carotid artery stenting systems and FDA-approved
or -cleared (effective December 9, 2009) embolic protection
devices. If deployment of the embolic protection device is not
technically possible, and not performed, then the procedure is not
covered by Medicare (effective December 9, 2009); •Patients who are
at high risk for CEA [Carotid Endarterectomy] and have symptomatic
carotid artery stenosis between 50 % and 70 %, in accordance with
the Category B IDE clinical trials regulation (42 CFR 405.201), as
a routine cost under the clinical trials policy (Medicare NCD
Manual 310.1), or in accordance with the NCD on carotid artery
stenting (CAS) post-approval studies (Medicare NCD Manual 20.7);
•Patients who are at high risk for CEA and have asymptomatic
carotid artery stenosis >80 %, in accordance with the Category B
IDE clinical trials regulation (42 CFR 405.201), as a routine cost
under the clinical trials policy (Medicare NCD Manual 310.1), or in
accordance with the NCD on CAS post- approval studies (Medicare NCD
Manual 20.7).
US Code:
42 USC 1395y(a)(1)(a) Name of Law: Exclusions from coverage and
Medicare as secondary
Due to adjustments in these
estimates, which were inaccurate due to an error, and the addition
of the Business Associate Privacy Agreement requirement to satisfy
HIPAA requirements and compliance, the burden has increased from
500 hours at $0 to 28,998 hours at $1,127,456.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.